{"id":47892,"date":"2022-09-01T13:02:02","date_gmt":"2022-09-01T11:02:02","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/enanta-pharmaceuticals-to-participate-in-two-investor-conferences-in-september\/"},"modified":"2022-09-01T13:02:02","modified_gmt":"2022-09-01T11:02:02","slug":"enanta-pharmaceuticals-to-participate-in-two-investor-conferences-in-september","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/enanta-pharmaceuticals-to-participate-in-two-investor-conferences-in-september\/","title":{"rendered":"Enanta Pharmaceuticals to Participate in Two Investor Conferences in September"},"content":{"rendered":"<div>\n<p>WATERTOWN, Mass.&#8211;(BUSINESS WIRE)&#8211;<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.enanta.com&amp;esheet=52848514&amp;newsitemid=20220901005100&amp;lan=en-US&amp;anchor=Enanta+Pharmaceuticals%2C+Inc.&amp;index=1&amp;md5=a5f50b99556bea3befbd1f42be45ff76\" rel=\"nofollow noopener\" shape=\"rect\">Enanta Pharmaceuticals, Inc.<\/a> (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in two investor conferences being webcast in September:\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20220901005100\/en\/1475183\/5\/Enanta_RGB.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20220901005100\/en\/1475183\/21\/Enanta_RGB.jpg\"><\/a><\/p>\n<ul class=\"bwlistdisc\">\n<li>\nWells Fargo Healthcare Conference: Presentation at 3:10 p.m. ET on September 8, 2022\n<\/li>\n<li>\nBaird Global Healthcare Conference: Fireside Chat at 9:40 a.m. ET on September 13, 2022\n<\/li>\n<\/ul>\n<p>\nA live webcast of each event will be accessible by visiting the \u201cEvents and Presentations\u201d section on the \u201cInvestors\u201d page of Enanta\u2019s website at <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.enanta.com&amp;esheet=52848514&amp;newsitemid=20220901005100&amp;lan=en-US&amp;anchor=www.enanta.com&amp;index=2&amp;md5=7a58d8ca23972d41138ca311fa6bb42c\" rel=\"nofollow noopener\" shape=\"rect\">www.enanta.com<\/a>. Replays of the webcasts will be available following the presentations and will be archived for approximately 30 days.\n<\/p>\n<p>\n<b>About Enanta Pharmaceuticals, Inc.<br \/>\n<br \/><\/b>Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. Enanta\u2019s research and development programs include clinical candidates currently in development for the following disease targets: respiratory syncytial virus (RSV), SARS-CoV-2 (COVID-19) and hepatitis B virus (HBV). Enanta is also conducting research in human metapneumovirus (hMPV).\n<\/p>\n<p>\nEnanta\u2019s research and development activities are funded by royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie. Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic HCV infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET\u00ae (U.S.) and MAVIRET\u00ae (ex-U.S.) (glecaprevir\/pibrentasvir). Please visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.enanta.com&amp;esheet=52848514&amp;newsitemid=20220901005100&amp;lan=en-US&amp;anchor=www.enanta.com&amp;index=3&amp;md5=4ad49ebf23ed20e204f807427594a7cd\" rel=\"nofollow noopener\" shape=\"rect\">www.enanta.com<\/a> for more information.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>Media and Investor Contact<\/b><br \/>Jennifer Viera<br \/>\n<br \/>617-744-3848<br \/>\n<br \/><a target=\"_blank\" href=\"m&#97;&#x69;&#x6c;t&#111;&#x3a;&#x6a;v&#105;&#101;&#x72;&#x61;&#64;&#101;&#x6e;&#x61;n&#116;&#x61;&#x2e;c&#111;&#109;\" rel=\"nofollow noopener\" shape=\"rect\">&#106;&#x76;i&#101;&#x72;a&#64;&#x65;n&#97;&#x6e;t&#97;&#x2e;&#99;&#x6f;&#x6d;<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>WATERTOWN, Mass.&#8211;(BUSINESS WIRE)&#8211;Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in two investor conferences being webcast in September: Wells Fargo Healthcare Conference: Presentation at 3:10 p.m. ET on &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/enanta-pharmaceuticals-to-participate-in-two-investor-conferences-in-september\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-47892","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Enanta Pharmaceuticals to Participate in Two Investor Conferences in September - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/enanta-pharmaceuticals-to-participate-in-two-investor-conferences-in-september\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Enanta Pharmaceuticals to Participate in Two Investor Conferences in September - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"WATERTOWN, Mass.&#8211;(BUSINESS WIRE)&#8211;Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in two investor conferences being webcast in September: Wells Fargo Healthcare Conference: Presentation at 3:10 p.m. ET on ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/enanta-pharmaceuticals-to-participate-in-two-investor-conferences-in-september\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-01T11:02:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220901005100\/en\/1475183\/21\/Enanta_RGB.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/enanta-pharmaceuticals-to-participate-in-two-investor-conferences-in-september\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/enanta-pharmaceuticals-to-participate-in-two-investor-conferences-in-september\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Enanta Pharmaceuticals to Participate in Two Investor Conferences in September\",\"datePublished\":\"2022-09-01T11:02:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/enanta-pharmaceuticals-to-participate-in-two-investor-conferences-in-september\\\/\"},\"wordCount\":284,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/enanta-pharmaceuticals-to-participate-in-two-investor-conferences-in-september\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220901005100\\\/en\\\/1475183\\\/21\\\/Enanta_RGB.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/enanta-pharmaceuticals-to-participate-in-two-investor-conferences-in-september\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/enanta-pharmaceuticals-to-participate-in-two-investor-conferences-in-september\\\/\",\"name\":\"Enanta Pharmaceuticals to Participate in Two Investor Conferences in September - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/enanta-pharmaceuticals-to-participate-in-two-investor-conferences-in-september\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/enanta-pharmaceuticals-to-participate-in-two-investor-conferences-in-september\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220901005100\\\/en\\\/1475183\\\/21\\\/Enanta_RGB.jpg\",\"datePublished\":\"2022-09-01T11:02:02+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/enanta-pharmaceuticals-to-participate-in-two-investor-conferences-in-september\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/enanta-pharmaceuticals-to-participate-in-two-investor-conferences-in-september\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/enanta-pharmaceuticals-to-participate-in-two-investor-conferences-in-september\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220901005100\\\/en\\\/1475183\\\/21\\\/Enanta_RGB.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220901005100\\\/en\\\/1475183\\\/21\\\/Enanta_RGB.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/enanta-pharmaceuticals-to-participate-in-two-investor-conferences-in-september\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Enanta Pharmaceuticals to Participate in Two Investor Conferences in September\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Enanta Pharmaceuticals to Participate in Two Investor Conferences in September - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/enanta-pharmaceuticals-to-participate-in-two-investor-conferences-in-september\/","og_locale":"en_US","og_type":"article","og_title":"Enanta Pharmaceuticals to Participate in Two Investor Conferences in September - Pharma Trend","og_description":"WATERTOWN, Mass.&#8211;(BUSINESS WIRE)&#8211;Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in two investor conferences being webcast in September: Wells Fargo Healthcare Conference: Presentation at 3:10 p.m. ET on ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/enanta-pharmaceuticals-to-participate-in-two-investor-conferences-in-september\/","og_site_name":"Pharma Trend","article_published_time":"2022-09-01T11:02:02+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220901005100\/en\/1475183\/21\/Enanta_RGB.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/enanta-pharmaceuticals-to-participate-in-two-investor-conferences-in-september\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/enanta-pharmaceuticals-to-participate-in-two-investor-conferences-in-september\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Enanta Pharmaceuticals to Participate in Two Investor Conferences in September","datePublished":"2022-09-01T11:02:02+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/enanta-pharmaceuticals-to-participate-in-two-investor-conferences-in-september\/"},"wordCount":284,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/enanta-pharmaceuticals-to-participate-in-two-investor-conferences-in-september\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220901005100\/en\/1475183\/21\/Enanta_RGB.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/enanta-pharmaceuticals-to-participate-in-two-investor-conferences-in-september\/","url":"https:\/\/pharma-trend.com\/en\/enanta-pharmaceuticals-to-participate-in-two-investor-conferences-in-september\/","name":"Enanta Pharmaceuticals to Participate in Two Investor Conferences in September - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/enanta-pharmaceuticals-to-participate-in-two-investor-conferences-in-september\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/enanta-pharmaceuticals-to-participate-in-two-investor-conferences-in-september\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220901005100\/en\/1475183\/21\/Enanta_RGB.jpg","datePublished":"2022-09-01T11:02:02+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/enanta-pharmaceuticals-to-participate-in-two-investor-conferences-in-september\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/enanta-pharmaceuticals-to-participate-in-two-investor-conferences-in-september\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/enanta-pharmaceuticals-to-participate-in-two-investor-conferences-in-september\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220901005100\/en\/1475183\/21\/Enanta_RGB.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220901005100\/en\/1475183\/21\/Enanta_RGB.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/enanta-pharmaceuticals-to-participate-in-two-investor-conferences-in-september\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Enanta Pharmaceuticals to Participate in Two Investor Conferences in September"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/47892","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=47892"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/47892\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=47892"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=47892"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=47892"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}